Shares of CymaBay Therapeutics Inc. (NASDAQ:CBAY) shot up 4.6% on Monday . The stock traded as high as $2.05 and last traded at $2.03, with a volume of 248,226 shares trading hands. The stock had previously closed at $1.94.

Several research firms have recently weighed in on CBAY. Zacks Investment Research upgraded shares of CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 12th. Roth Capital began coverage on shares of CymaBay Therapeutics in a research note on Friday, July 1st. They issued a “buy” rating for the company. Finally, HC Wainwright lowered shares of CymaBay Therapeutics from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $6.00 to $2.25 in a research note on Wednesday, June 1st.

The firm’s 50 day moving average is $1.74 and its 200-day moving average is $1.72. The company’s market capitalization is $51.82 million.

CymaBay Therapeutics (NASDAQ:CBAY) last issued its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.32) by $0.02. Equities research analysts expect that CymaBay Therapeutics Inc. will post ($1.21) earnings per share for the current fiscal year.

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.